RET and thyroid gland carcinoma: N-desmethylvandetanib and vandetanib-N-oxide were identified as the two major oxidation products of vandetanib, the drug used for the treatment of symptomatic or progressive medullary thyroid cancer due to the RET tyrosine kinase mutation occurring in this type of thyroid cancer.